Roche invests in Genmab  

Swiss medical giant Roche invests USD 20 million in Danish biotech company

Børsen Online reports today that Swiss medical giant Roche and Genmab in Denmark are extending their cooperation in the development of human antibodies. Roche is also investing a massive DKK 170 million (USD 20 million) in the Zealand-based biotech company. Genmab expects to launch 15 new projects over the next 12 months. The cooperation means that if all development objectives are met, Genmab will rake in some DKK 850 million (USD 100 million) in royalties. Genmab has a range of products under development, including treatments for cancer, rheumatoid arthritis and infectious diseases.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×